Home-care guidelines for patients with COVID-19

General advice for the care of children with COVID-19

In Australia, to date, there have been very few hospital admissions required for children due to COVID-19 illness severity. Children are significantly less likely to suffer severe COVID-19 than adults and many children with COVID-19 will be asymptomatic. Common symptoms are similar to those of adults, including rhinorrhoea, cough, sore throat, fever and gastrointestinal symptoms. They might also suffer headaches, myalgia, or loss of taste or smell. They are much less likely to suffer breathlessness, and this symptom should escalate clinical assessment.

The National COVID-19 Clinical Evidence Taskforce provides recommendations for children and adolescents in regard to disease-modifying treatments, chemoprophylaxis and respiratory support for the management of COVID-19.

In most cases, only children meeting criteria for the low-risk monitoring protocol (refer to Box 5) should be managed in the community. It might be appropriate for GPs to care for children with moderate risk factors depending on local requirements, resources and escalation pathways.

Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2’ (PIMS-TS A inflammatory condition has been described in children and adolescents settings with significant COVID-19 community transmission, known as ‘Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2’ (PIMS-TS) or ‘Multisystem Inflammatory Syndrome in Children [MIS-C]’ as it is referred to in the United States of America. PIMS-TS usually presents 2–6 weeks after the acute infection, which may be asymptomatic.  PIMS-TS  should be considered in an unwell child or adolescent with persistent fever (lasting more than 72 hours), signs of shock, rash and abdominal pain, and there may be several features overlapping with Kawasaki disease and toxic shock syndrome. 21

If PIMS-TS is suspected, early transfer to a paediatric hospital with ICU facilities should be considered due to potential for rapid deterioration.

  1. Communicable Diseases Network Australia. Coronavirus Disease 2019 (COVID-19): CDNA National guidelines for public health units. Version 6.7. Canberra: Department of Health, 2022 Content/cdna-song-novel-coronavirus.htm [Accessed 13 May 2022].
  2. Australian Technical Advisory Group on Immunisation. Clinical guidance for COVID-19 vaccine providers. Canberra; ATAGI, 2022 [Accessed 13 May 2022].
  3. Department of Health. How COVID-19 vaccines work. Canberra, 2022 vaccines/how-they-work [Accessed 19 may 2022].
  4. Rees S, Fisher J. COVID-19 and the mental health of people from refugee backgrounds. Int J Health Serv 2021;50(4):415–17. doi: 10.1177/0020731420942475.
  5. National COVID-19 Clinical Evidence Taskforce. Management of adults with mild COVID-19 (version 42.1). Melbourne, 2022 [Accessed 19May 2022].
  6. Community Health Pathways – NSW Collaboration. COVID-19 Active Case Management, 2022.
  7. National COVID-19 Clinical Evidence Taskforce. Pathways to care for adults with COVID-19 (version 4.2). Melbourne: National COVID-19 Clinical Evidence Taskforce, 2022 [Accessed 19 May 2022].
  8. Agency for Clinical Innovation. Caring for adults and children in the community with COVID-19. Sydney: NSW Health, 2022 [Accessed 19 May 2022].
  9. National COVID-19 Clinical Evidence Taskforce. Pathways to care for children and adolescents with COVID-19 (version 2.1). Melbourne: National COVID-19 Clinical Evidence Taskforce, 2022 [Accessed 19 May 2022].
  10. National COVID-19 Clinical Evidence Taskforce. Steroids for people with asthma or COPD and COVID-19. Melbourne: National COVID-19 Clinical Evidence Taskforce, 2022 [Accessed 19 May 2022].
  11. National COVID-19 Clinical Evidence Taskforce. ACEIs/ARBs in patients with COVID-19. Melbourne: National COVID-19 Clinical Evidence Taskforce, 2022 [Accessed 19 May 2022].
  12. National COVID-19 Clinical Evidence Taskforce. Oestrogen-containing therapies. Melbourne: National COVID-19 Clinical Evidence Taskforce, 2022 [Accessed 10 June 2022].
  13. Cagnacci A, Bonaccorsi G, Gambacciani M, Board of the Italian Menopause Society Collaborators. Reflections and recommendations on the COVID-19 pandemic: Should hormone therapy be discontinued? Maturitas, 2020;138:76–77. doi: 10.1016/j.maturitas.2020.05.022.
  14. Australian Government Department of Health. Lagevrio (molnupiravir) PBS Factsheet. Canberra: DoH, 2022 [Accessed 11 July 2022]
  15. Australian Government Department of Health. Paxlovid® (nirmatrelvir and ritonavir) Pharmaceutical Benefits Scheme Factsheet. Canberra: DoH, 2022 [Accessed 11 July 2022]
  16. National COVID-19 Clinical Evidence Taskforce. Corticosteriods (systemic) for adults. Melbourne: National COVID-19 Clinical Evidence Taskforce, 2022 [Accessed 19 May 2022].
  17. Australian Government Department of Health. Guidance on the use of personal protective equipment (PPE) for health care workers in the context of COVID-19. Canberra: DoH, 2021 [Accessed 19 May 2022].
  18. Infection Control Expert Group. Information about cleaning and disinfection for health and residential care facilities. Canberra: Australian Government, 2020 coronavirus-covid-19-environmental-cleaning-and-disinfection-principles-for- health-and-residential-care-facilities-coronavirus-covid-19-environmental- cleaning-and-disinfection-principles-for-health-and-residential-care-fac.pdf [Accessed 19 May 2022].
  19. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Melbourne: RACGP, 2021. A message for pregnant women and their families information-for-pregnant-women [Accessed 19 May 2022]
  20. National COVID-19 Clinical Evidence Taskforce. Pregnancy and Perinatal care. Melbourne: National COVID-19 Clinical Evidence Taskforce, 2022 [Accessed 19 May 2022].
  21. The Royal Children’s Hospital Melbourne. Clinical Practice Guidelines – COVID-19. Melbourne: The Royal Children’s Hospital Melbourne, 2021 org.au/clinicalguide/guideline_index/COVID-19/ [Accessed 19 May 2022].
  22. National COVID-19 Clinical Evidence Taskforce. Management of people with COVD-19 who are older and living with frailty and/or cognitive impairment (version 5.0). Melbourne: National COVID-19 Clinical Evidence Taskforce, 2021 V5.0.pdf?=210701-72551 [Accessed 18 May 2022].

Advertising